Microcap Ledger Zura Bio Ltd $ZURA
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- La Jolla, CA
- Fiscal year end
- December 31
- Shares outstanding
- 95,829,137 [10-Q 2026-08-11]
What the company doesAI summary of filing
Zura Bio Ltd is a clinical-stage biotechnology company developing monoclonal antibody and bispecific antibody therapeutics for autoimmune and inflammatory diseases. The company has in-licensed three product candidates: tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; crebankitug (ZB-168), targeting IL-7 receptor alpha; and torudokimab (ZB-880), targeting IL-33. Zura is currently running two Phase 2 clinical trials for tibulizumab in hidradenitis suppurativa and diffuse cutaneous systemic sclerosis, with the other two candidates undergoing assessment for future development strategies. The company has not completed any Phase 2 or Phase 3 clinical trials, has no approved products, generates no revenue from product candidates, and expects to incur significant losses for the foreseeable future. [10-K 2026-03-19]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$50.53M | −$39.8K | $205.13M | [10-Q 2026-08-11] |
| FY ended Dec 2025 | — | −$68.65M | −$64.81M | $109.41M | [10-K 2026-03-19] |
| FY ended Dec 2024 | — | −$52.40M | −$28.08M | $176.50M | [10-K 2026-03-19] |
- Quarterly cash burn
- −$19.9K
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-04 | 65,293,530 | [10-Q 2024-11-07] |
| 2025-03-21 | 68,374,998 | [10-K 2025-03-25] |
| 2025-05-05 | 61,874,998 | [10-Q 2025-05-08] |
| 2025-08-04 | 65,018,058 | [10-Q 2025-08-14] |
| 2025-11-10 | 65,023,308 | [10-Q 2025-11-13] |
| 2026-03-16 | 94,880,710 | [10-K 2026-03-19] |
| 2026-05-04 | 94,997,710 | [10-Q 2026-05-07] |
| 2026-08-11 | 95,829,137 | [10-Q 2026-08-11] |
- Shelf registration
- S-3 filed 2024-09-03; declared effective 2024-09-17 [S-3 2024-09-03]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-17 | 8-K | Regulation FD disclosure |
| 2026-08-11 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-08-11 | 10-Q | Quarterly report |
| 2026-07-01 | 8-K | Regulation FD disclosure |
| 2026-06-18 | 8-K | Director or officer change; Shareholder vote results |
| 2026-05-22 | 8-K | Director or officer change |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-12 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-07 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-05-07 | 10-Q | Quarterly report |
| 2026-05-06 | 13G/A | Beneficial ownership report (5%+ holder) |
Alerts for $ZURA
Email me when Zura Bio Ltd files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.